The genetics field has become increasingly popular in recent years thanks to improvements in technology, which is probably why San Francisco-based Invitae feels confident enough to go public. The genetics company has announced that it has filed for an IPO an hopes to raise $86.3 million from stock sales.
The San Francisco-based genetics company Invitae Corporation said Friday that it has filed an S-1 with the Securities and Exchange Commission, pointing to the company’s intention to become a public company. The company expects to raise $86.3 million dollars from the sale of stock, according to the filing. J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. Cowen and Company, LLC and Leerink Partners LLC are acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined. Invitae intends to apply to list its common stock on The New York Stock Exchange under the symbol “NVTA.”
